Perspective Therapeutics (NYSE:CATX) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at […]
HC Wainwright initiated coverage on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at […]
